CALI: calcimedica.com Company Value to Net Income

CalciMedica Corp - graphic logo of issuer CALI

CalciMedica, Inc. (CALI) generates revenue by bringing immunotherapeutic agents to market, specifically drugs targeting pulmonary inflammation and pancreatitis. This chart reflects a market valuation of 0.00. The company is implementing software robots for clinical analysis and automating molecule screening. Its status as an innovator in acute care therapy helps the brand gain recognition among intensivists by preventing multi-organ failure.

calcimedica.com (CALI) Price to Earnings Ratio: for the period 10/11/2024 - 10/17/2026

Analytical breakdowns for CalciMedica Corp (CALI)

- price and consensus price forecast:
- market capitalization information:
Comprehensive company analysis:CalciMedica CALI
Signature product of CalciMedica Inc

P/E is calculated as the ratio of market capitalization to net income, measuring the cost of one dollar of annual earnings. This ratio allows conservative capital to filter out speculative bubbles and avoid overpaying for overheated assets. For CalciMedica, Inc. (CALI), which depends on strict FDA control and venture capital infusions, the metric reflects market expectations for Auxora patents. By analyzing the P/E valuation trend, an investor can determine the extent to which the company's biotechnological prospects are overvalued.

Key competitors

P/E Multiple Argenx|Price to Earnings Ratio BNTX (BioNTech Group)|ABVX (abivax.com) - Company Value to Net Income|P/E Multiple ADMA (admabiologics.com)|Business Payback Period protagonist-inc.com (PTGX)|IMVT - Price to Earnings Ratio|Kiniksa Pharmaceuticals, Ltd. (KNSA) - Price to Earnings Ratio|Grifols Biemat (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotechnologies|Price to Earnings Ratio CLDX|P/E Multiple auriniapharma.com|Price to Earnings Ratio BioCryst Pharmaceuticals Inc (BCRX)|Vera Therapeutics - Price to Earnings Multiple|P/E Multiple DNTH (dianthustx.com)|Pharvaris Pharma (PHVS) - Market Cap to Earnings|AbCellera Biologics - P/E Multiple|tourmalinebio.com - Market Price to Net Income Ratio|Precigen (PGEN) - Price to Earnings Ratio|Pharming Group - Company Value to Net Income|Price to Earnings Ratio Nektar Therapeutics Inc|UPB (Upstream Pharma) - Market Price to Net Income Ratio|P/E Multiple ZBIO|P/E Multiple immunome.com (IMNM)|P/E Multiple GOSS (gossamerbio.com)|Business Payback Period KalVista Pharma (KALV)|SEPN - Price to Earnings Ratio|Business Payback Period Pieris Pharmaceuticals PVLA|SVRA (Savara Inc.) - Price to Earnings Ratio|Market Cap to Net Income RIGL (Rigel Pharmaceuticals)|ANAB (AnaptysBio) - P/E Multiple|ATXS (Astria Therapeutics, Inc.) - Market Price to Net Income Ratio|Price to Earnings Ratio engene.com (ENGN)|RAPT (RAPT Therapeutics, Inc.) - Company Value to Net Income|Aerovate Therapeutics - Price to Earnings Ratio|Company Value to Net Income ACRS|Kyverna Therapeutics, Inc - P/E Multiple|Market Cap to Net Income TLSA|CABA: P/E Multiple|Price to Earnings Ratio Ventyx Bio|Price to Earnings Ratio Theratechnologies, Inc.|Market Cap to Earnings Avalo Therapeutics AVTX|P/E Multiple ELDN|AGEN (Agenus, Inc.) - Company Value to Net Income|Price to Earnings Ratio Climb Bio, Inc. CLYM|Zura Bio Limited (ZURA) - Market Cap to Earnings|ATYR: Price to Earnings Ratio|adagene.com (ADAG) - Price to Earnings Ratio|Ikena Oncology (IMA) - Price to Earnings Ratio|Price to Earnings Ratio Shattuck Labs, Inc.|Price to Earnings Ratio equilliumbio.com|Price to Earnings Ratio connectbiopharm.com (CNTB)|P/E Multiple IMUX|Business Payback Period Atara Bio|Price to Earnings Ratio InflaRx N.V. IFRX|X4 Pharmaceuticals - Price to Earnings Ratio|ACET: Price to Earnings Ratio|Company Value to Net Income CELU (celularity.com)|INMB: P/E Multiple|BRNS: Market Price to Net Income Ratio|KZR (Kezar Life Sciences, Inc.) - P/E Multiple|SAB Biotherapeutics Inc. (SABS) - Business Payback Period|P/E Multiple AKTX|Price to Earnings Ratio ENLV (Enlivex Therapeutics Ltd)|Price to Earnings Ratio Q32 Bio Inc. QTTB|GOVX - Price to Earnings Ratio|EDSA - Price to Earnings Ratio|Market Cap to Earnings iBio|CARM: P/E Multiple|Market Cap to Net Income XTLB (XTL Biopharmaceuticals, Ltd.)|Price to Earnings Ratio boltbio.com|P/E Multiple HCW Biologics|P/E Multiple APVO|AIM - Market Cap to Earnings|P/E Multiple ADTX (Aditxt Inc.)|Business Payback Period GRI Bio, Inc. (GRI)|XRTX - Price to Earnings Ratio|reshapelifesciences.com (HIND) - Price to Earnings Ratio|REVB: P/E Multiple|Indaptus Therapeutics, Inc. - Company Value to Net Income|Price to Earnings Ratio Scinai|affimed.com - Market Cap to Net Income|Price to Earnings Ratio allakos.com (ALLK)|P/E Multiple HOOKIPA Pharma, Inc. (HOOK)|IGM Biosciences Inc. - Price to Earnings Ratio|iTeos Therapeutics, Inc. (ITOS) - Market Cap to Earnings|OCEA: Price to Earnings Ratio|Company Value to Net Income TCBP (TC BioPharm (Holdings) PLC)|THRD: P/E Multiple